NCT03829306: Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)

NCT03829306
Breast Cancer Type: HER2+
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have previously received trastuzumab + taxane, separately or in combination, & are planning to receive T-DM1 (Kadcyla)
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03829306

Comments are closed.

Up ↑